CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Complete Title: A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors
Trial Phase: I
Investigator: Jennifer Specht
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
Bile Duct Cancer
Head and Neck Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Neoplasms, Squamous Cell
Lung Carcinoma, Small-Cell
Biliary Tract Neoplasms
Gastroesophageal Junction Cancer
Carcinoma, Transitional Cell
Carcinoma, Small Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors